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Abstract
Background: Three transketolase genes have been identified in the human genome to date: transketolase (TKT),
transketolase-like 1 (TKTL1) and transketolase-like 2 (TKTL2). Altered TKT functionality is strongly implicated in the
development of diabetes and various cancers, thus offering possible therapeutic utility. It will be of great value to
know whether TKTL1 and TKTL2 are, similarly, potential therapeutic targets. However, it remains unclear whether
TKTL1 and TKTL2 are functional transketolases.
Results: Homology modelling of TKTL1 and TKTL2 using TKT as template, revealed that both TKTL1 and TKTL2
could assume a folded structure like TKT. TKTL1/2 presented a cleft of suitable dimensions between the homodimer
surfaces that could accommodate the co-factor-substrate. An appropriate cavity and a hydrophobic nodule were
also present in TKTL1/2, into which the diphosphate group fitted, and that was implicated in aminopyrimidine and
thiazole ring binding in TKT, respectively. The presence of several identical residues at structurally equivalent
positions in TKTL1/2 and TKT identified a network of interactions between the protein and co-factor-substrate,
suggesting the functional fidelity of TKTL1/2 as transketolases.
Conclusions: Our data support the hypothesis that TKTL1 and TKTL2 are functional transketolases and represent
novel therapeutic targets for diabetes and cancer.
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Background
Three transketolase genes have been identified in the human
genome to date. Transketolase (EC 2.2.1.1; TKT) is a crucial
enzyme that links the pentose phosphate pathway (PPP), a
non-oxidative glucose pathway (NOGP), to glycolysis. The
TKT gene is located on chromosome 3 at position 3p21.1
and is responsible for generating sugar phosphates for intra-
cellular nucleotide metabolism as well as for the production
of nicotinamide adenine dinucleotide phosphate (NADPH),
a reducing agent and anti-oxidant [1]. TKT is a homodimer
and known thiamine diphosphate (TDP)-dependent enzyme
that possesses two active sites located at the monomer con-
tact surfaces [2, 3]. In addition to TKT, transketolase-like 1
(TKTL1) and transketolase-like 2 (TKTL2) loci are found
on the X chromosome at Xq28 and on chromosome 4 at
4q32.2, respectively [1].
An altered function of transketolase is linked to vari-
ous pathophysiologic complications, suggesting TKT as a
potential therapeutic target. TKT is the best studied
transketolase, and previous studies reported an altered
activity in patients suffering from diabetes and various
cancers [3–5]. For example, hyperglycemic individuals
display lowered TKT activity that may be ameliorated by
thiamine treatment, thus offering potential as a novel
treatment for type 2 diabetes [6]. TKT pathways are also
intricately involved in cancer progression and metastasis.
For example, PPP activation satisfies the high demand
by cancer cells for nucleotides (to ensure proliferation)
by the terminal conversion of glucose to ribose and
conversion to lactate. Moreover, TKT inhibition by oxy-
thiamine (a thiamine antagonist) substantially decreased
pancreatic cancer cell growth [7]. Taken together, these
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studies strongly implicate perturbed TKT function in the
development of diabetes and various cancers [8].
What about TKTL1 and TKTL2? There is limited infor-
mation regarding the role of TKTL2; more is known about
TKTL1. TKTL1, previously postulated to be a pseudogene,
encodes a transketolase like-protein that is also linked to
cancer [9]. For example, TKTL1 mutations are associated
with cancers, making it a promising target for anti-cancer
treatments [6, 10]. TKTL1 silencing in colon cancer cells
attenuated cell proliferation, and significantly decreased
TKT activity, suggesting an interplay between the two
transketolases [11]. However, some researchers found that
this relationship was experimentally variable [12].
Human TKTand TKTL1 differ in both primary structure
and in amino acid composition [13], and several groups
have raised doubt whether TKTL1 indeed was an actual
transketolase [14, 15]. There are no experimental data con-
firming the enzymatic activity of TKTL1 compared to
TKT. TKTL1 has 38 amino acids less in the active site
compared to TKT, and this may affect its enzymatic activ-
ity. TKTL1 also lacks two vital histidine residues that are
otherwise conserved in transketolases, and are required for
catalytic processes [15]. There is also a substitution muta-
tion (W124S) in the TKTL1 amino acid sequence. More-
over, the functional identity of TKTL1 and TKTL2 as
possible transketolases was based only on an analysis of
the one-dimensional sequence alignment of these proteins
with the structure of human TKT [13]. A significant limita-
tion of such an approach is that it could miss the identifi-
cation of alternative residues and possible interactions that
may be involved in co-factor and substrate binding.
In light of conflicting findings and uncertainties, the
current study investigated the possible function of TKTL1
and TKTL2 as putative transketolases. We employed hom-
ology modelling and structural analysis of TKTL1 and
TKTL2 using the 0.97 Å crystal structure of TKT in com-
plex with a TDP co-factor-substrate as the template [13].
Materials and methods
Modelling
To assess the relationship between TKT and transketolase-
like proteins, we performed a multiple alignment of several
transketolase enzyme sequences that included the putative
transketolase family members TKTL1 and TKTL2. The
multiple alignment revealed a high degree of conservation
among the mammalian enzymes (Fig. 1). Sequence regions
present in yeast and Escherichia coli TKT, that appear to
have been lost in the mammalian group enzymes during
evolution, map to unstructured regions between α5-β2 and
α9-β6 and within the α9 and α12 helices (Fig. 1). These
deletions, however, do not abolish the functionality of the
mammalian TKT [16]. Within the mammalian group of
transketolase enzymes, TKTL1 contains an additional
deletion from G76 to P113. This incorporates α4 and
310-helix 5 (η5), including H77, that is involved in
stabilizing TDP in the active site of TKT. However, as
we show below, this deletion does not affect the over-
all structure of the modeled TKTL1 enzyme and the
absence of an H77 homolog may be compensated for by
alternative stabilizing interactions to TDP. TKTL2 does
not contain this deletion and is 64% identical and 92% con-
served compared to TKT in this region (Fig. 1). TKTL1 is
60% identical and 81% conserved relative to TKT.
We performed a PHI-BLAST search and identified
human TKT (UniProtKB P29401) as an appropriate tem-
plate for modelling (Fig. 1). A co-crystal structure of this
protein in complex with ketose D-xylulose-5-phosphate
(X5P) is available at a resolution of 0.97 Å (PDB 4KXW)
[17]. We generated multiple homology models of TKTL1
and TKTL2 using this crystal structure and the Robetta
[18] and SwissProt servers [19]. Although all models were
energy minimized, we did not proceed with molecular
dynamics simulations, thinking that an additional predict-
ive refinement would contribute little to our primary
structural analysis.
Model verification
We verified the TKTL1 and TKTL2 model qualities using
MolProbity [20] and Verify3D [21] available on the SAVE
server (services.mbi.ucla.edu/SAVES). The Verify3D method
calculates a 3D-1D score for the presence of a given residue
within its environment in the calculated model and reports
the average score in a sliding 21-residue window. For
the TKTL1 model, 96% of the residues have a 3D-1D
score > 0.2, where Verify3D defines a score of > 0.2
for more than 80% of the residues as acceptable. The
Ramachandran plot showed that 98.7% (585/593) of
all residues were in allowed regions, 99.8% of all rota-
mers were favored and no bad rotamers were present
in the model. In the TKTL2 model, 93% of residues had a
3D-1D score > 0.2, 99.4% (625/626) of residues had ϕ and
ψ angles within the allowed regions, no bad rotamers were
present and 98.2% of the rotamers were favored. By com-
parison, in the crystal structure of TKT [17], 92% of resi-
dues had a 3D-1D score > 0.2, 99.7% of residues exhibited
favored ϕ and ψ angles, 94% were favored rotamers and
3% bad rotamers were present, emphasizing the quality of
our proposed models.
Fitting the TDP substrate ligand in the TKTL1 and TKTL2
models
To allow analysis of the substrate binding to the modeled
TKTL1 and TKTL2, chain A of human transketolase, crys-
tallized as a covalent complex with its physiological sub-
strate X5P (PDB accession: 4KXW), was aligned to chain A
of the TKTL1 or TKTL2 model using the Matchmaker tool
in Chimera [22, 23]. This superposition gave a RMSD
(α-carbon) of 0.4 and 0.3 Å for the TKTL1 and TKTL2
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models, respectively, and placed the X5P ligand in the same
relative position in the model compared to its position in
the TKT crystal structure (Fig. 2a and b, Figure S1A). The
region G76 to P113 of TKT, absent in TKTL1, is shown by
the green section and the H77 and H110 residues (where
H77 was proposed to be involved in binding to TDP) are
shown in yellow (Fig. 2a). Note that the peptide chain in
TKTL1 proceeds smoothly as an unstructured coil from
A82 to D89, bypassing the α4 and η5 secondary structures
observed between S74 and D119 in TKT (Fig. 2a). The ab-
sence of this section of the structure appears to have negli-
gible impact on the global structure of the modeled
TKTL1, based on the close structural co-alignment (α-car-
bon RMSD= 0.4 Å) of the minimized model (Fig. 2a and b,
Figure S1A).
Results
Homology models of TKTL1 and TKTL2 show substrate clefts
The binding of the TDP substrate and substrate adduct
in the active site of TKT has been pursued by a number
of previous studies [13, 16, 17]. For the current study,
TDP fits in a channel formed at the interface surfaces of
the homodimer subunits (Fig. 2c). When viewing the
position of the aligned TDP ligand in the structure of
the modeled TKTL1, the interface surface between the
homodimer subunits similarly provides a crevice into
which the TDP fits (Fig. 2d; Figure S1B shows a similar
crevice in TKTL2). TKTL1 provides a surface architec-
ture, distribution of polar/hydrophobic regions and
spatial placement of residue sidechains very similar to
that found in the TKT crystal structure. This allows for
the stabilization of the bound TDP in a similar orienta-
tion relative to key surface elements, and the two identi-
fied active site residues.
Identical and similar hydrogen-bonds stabilize the TDP
diphosphate in TKTL1/2
For TKT the TDP diphosphate group is inserted into a
cavity on the surface and this is coordinated with an Mg2+
cation (Fig. 2e). Several hydrogen-bonds are made to the
(See figure on previous page.)
Fig. 1 The multiple alignment of TKT, TKTL1 and TKTL2. The multiple alignment of human (P29401.3), mouse (P40142.1), Escherichia coli (P27302.5) and
Saccharomyces cerevisiae (P23254.4) transketolase (TKT) sequences as well as human transketolase-like protein 1 (TKTL1) (P51854.2) and 2 (TKTL2)
(Q9H0I9.1) sequences. The secondary structures visible in the human TKT crystal structure (PDB accession 4KXW) is shown aligned above the human
TKT sequence. The α-helices, 310-helices and β-strands are indicated. Identical and conserved residues at aligned sequence positions are identified by
red and yellow blocks, respectively. The alignment was calculated with T-coffee [33] and the alignment figure generated with ESPript [34]
A C E
B D F
Fig. 2 Homology of TKTL1. Homology model of TKTL1 based on the TKT co-crystal structure with a TDP-D-xylulose-5-phosphate (X5P) adduct. a
Ribbon representation of the homodimer (tan and blue sub-units) of TKT with the TDP-X5P adduct ligand shown as red spheres. The η1, α4 and η2
helices (green), as well as H77 and H110 (yellow) (absent in TKTL1) are shown. b Homology model of TKTL1 shown as a homodimer (tan and blue
sub-units) and fitted to the coordinates of TKT to show the location of the substrate adduct, indicated by the red spheres. c The ligand present in the
substrate cleft that is formed between the surfaces of the two units in the TKT homodimer is shown. d A similar substrate cleft is visible between the
two units of the homodimer in the homology model of TKTL1. e A di-phosphate binding cavity in visible on the surface within the substrate cleft of
each monomer in the TKT homodimer. f A di-phosphate binding cavity is also visible within the substrate cleft of the TKTL1 homology model
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phosphate oxygen atoms by residue side-chains that
protrude into the cavity volume. This includes hydrogen-
bonds from the G156 and E157 backbone amide groups,
the K75 and K244 ε-NH2, the N185 NH2 and the S40 hy-
droxyl and H77 τ-NH groups (Fig. 3a). Hydrogen-bonds
were identified in Chimera using the criteria of Mills
and Dean. [24] When analyzing the TKTL1 model, the
diphosphate group of TDP is similarly inserted into a
surface cavity (Fig. 2f; the cavity in TKTL2 is shown in
Figure S1C) and a network of possible hydrogen-bond
interactions can be observed in the binding to the TDP
diphosphate (Fig. 3b). A similar series of hydrogen bonds
involving the equivalent residues are visible in TKTL2
(Figure S2A). Importantly, TKTL1 lacks the equivalent of
H77 and there is no alternative residue in a suitable pos-
ition that can substitute for H77. However, five groups are
involved in hydrogen-bonding to the TDP diphosphate in
TKTL1. These include the E127 backbone amide, the K83
and K217 ε-NH2, the N155 NH2 and the S48 hydroxyl
groups (Fig. 3b). It is likely that this extensive set of inter-
actions, combined with the coordinate binding to the lo-
calized Mg2+, is sufficient to retain the TDP diphosphate
tail stably bound within the cavity. TKTL2 contains H78
at the equivalent position of TKT H77, and the former
residue makes a similar hydrogen-bond to the
β-phosphate hydroxyl group (Figure S2A; refer Additional
files 1 and 2 for TKTL1 and TKTL2 in covalent complex
X-ray diffraction data).
Interactions with the aminopyrimidine and thiazole rings
Numerous residues that are contributed by both subunits
of the homodimer are involved in interactions with the
aminopyrimidine and thiazole rings of TDP. N189, H258,
Q428, G125 and E366 were previously identified to be
involved in a hydrogen-bond network with the TDP ring
structures [13, 16, 17] (Fig. 4a). The T342, I364, L125,
F389 and F392 side-chains were proposed to be involved
in non-polar and hydrophobic interactions with the TDP
rings [13, 16, 17] (Fig. 4a). A similar array of potential
interacting residues are found in the TKTL1 (Fig. 4b) and
TKTL2 models (Figure S2B). There are many identical
residues present at similar positions relative to the
TDP ligand in the TKTL1 model, e.g. the equivalent
TKT-TKTL1 residue pairs H258-H231, Q428-Q421,
E366-E369, G123-G93, F389-F362, F392-F365,
T342-T342 and L125-L95. Two residues that may be
involved in binding in TKT are absent in TKTL1, but
may be substituted by residues in comparable positions
that can participate in a similar interaction. For instance,
I364 of TKT is absent in TKTL1, but may be substituted
by M337. N185 is similarly absent in TKTL1, but H158 is
observed at a similar position, where the τ-NH group of
the imidazole ring may be involved in a hydrogen-bond to
the thiazole sulphur (Fig. 4b). In the case of TKTL2 the
residues H262, Q432, E370, G124, F393, F396, T346, L126,
I368 and N186 matches the corresponding residues in
TKT (Figure S2B).
Binding of the substrate in TKTL1/2
The co-crystal structure of TKT and the TDP co-factor re-
veals a reaction intermediate, a covalent adduct between
X5P and TDP [17]. The sugar adduct is stabilized in the
active site by a series of hydrogen bonds between H37,
H258 and H110, and the hydroxyl groups on C1, C3 and
C4 of the X5P (Fig. 5a). TKTL1 lacks H110 and there does
not seem to be another residue in a suitable position to
make a hydrogen-bond to C1 of X5P. However, an exten-
sive network of hydrogen-bonds is still associated with the
sugar adduct in the active site. Both H389 and S318 make
hydrogen-bonds to the X5P phosphate group, while
A B
Fig. 3 Binding of TDP to enzyme. Binding of the thiamine diphosphate (TDP) group to the enzyme. The residues involved in hydrogen bonding
to the di-phosphate group of TDP are shown for (a) TKT and (b) TKTL1. The equivalent of TKT H77 is not present in TKTL1
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H45 and H231 make hydrogen-bonds to the C3 and
C4 hydroxyl groups of X5P (Fig. 5b). In the case of
TKTL2, Q38 substitutes for TKT H37, and is seen to
make a similar hydrogen-bond to X5P C3 (Figure
S2C). The residues equivalent to TKT H258 and H110
are present as H262 and H111 in TKTL2, and make
hydrogen-bonds to C1 and the thiazole sulphur
(Figure S2C). The residues involved in interactions
with the co-factor in TKT, TKTL1 and TKTL2 are
summarized in Fig. 6.
Discussion
We have constructed homology models for TKTL1 and
TKTL2 using the crystal structure of human TKT in com-
plex with a reaction intermediate of the TDP co-factor as a
structural template. This allows a more rigorous assessment
of the possible enzyme-co-factor and enzyme-substrate in-
teractions compared to a simple alignment of sequences.
When employing superposition of models with the TKT
crystal structure to position the co-factor adduct in the
models, we have shown that a similar co-factor and
substrate crevice is formed at the interface between the two
sub-units of the homodimer in the TKTL1 and TKTL2
models (Fig. 2c and d and Figure S1B). This location of the
co-factor adduct further allowed the required insertion of
the TDP diphosphate tail into a cavity, where numerous
conserved and new interactions were possible that an-
chored TDP to the protein (Fig. 2e and f and Figure S1B,
Fig. 5 and Figure S2A). The environment and spatial distri-
bution of residues similarly allowed mostly conserved inter-
actions in TKTL1 and TKTL2 with the aminopyrimidine
and thiazole rings (Fig. 4 and Figure S2B). The residues that
may be involved in interactions with the TDP co-factor and
X5PA intermediate in TKT [13] and the equivalent
residues identified here in the TKTL1 and TKTL2 models
are summarized in Fig. 6.
A hydrophobic knob observed in TKT was also formed
by L95 and L125 in TKTL1 and TKTL2, respectively
(Fig. 7). This protrusion is associated with the methylene
group connecting the aminopyrimidine and thiazole rings
of TDP and stabilized the co-factor in the active site.
Numerous hydrogen-bonds to the X5P hydroxyl groups
A B
Fig. 4 Binding of thiamine backbone to the enzyme. The residues involved in hydrogen bonds, hydrophobic interactions and stacking
interactions in (a) TKT and (b) TKTL1 are shown. The residues indicated by asterisks have been implicated in catalysis
A B
Fig. 5 Binding of X5P to TKT. Binding of D-xylulose-5-phosphate (X5P) in the active site of TKT. Residues and water molecules involved in
hydrogen bonding to the xylulose adduct are shown for (a) TKT and (b) TKTL1
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Fig. 6 Interaction between TDP and TKT. Interactions between thiamine diphosphate (TDP) co-factor and the xylulose adduct, and residue
sidechains and peptide backbone in the active site of TKT. Residues and backbone groups involved in hydrogen bonding, hydrophobic
interactions and stacking interactions are indicated, based on the analysis of Tittmann and co-workers [6]. The equivalent residues in TKTL1 and
TKTL2, based on the multiple alignment shown in Fig. 1, are indicated for each residue (order TKT, TKTL1 and TKTL2, top to bottom, in each
square). Residues that are absent or not identical in the alignment are indicated
A B C
Fig. 7 Hydrophobic interactions with aminopyrimidine and thiazole rings. Association of thiamine diphosphate (TDP) with a hydrophobic nodule.
The aminopyrimidine and thiazole rings (linked by a methylene bridge) is stabilized in a V-conformation by binding of the di-phosphate in a
cavity, and association of a hydrophobic nodule formed by (a) L125 in TKT, (b) L95 in TKTL1, and (c) L126 in TKTL2, with ring structures. The
molecular surface is shown colored according to the Kyte-Doolittle hydrophobic value in the range − 4.5 (purple) to 4.5 (tan)
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were also conserved in TKTL1 and TKTL2 and are
expected to stabilize the reaction intermediate. Taken
together, the sum of these interactions to the diphos-
phate tail, aminopyrimidine and thiazole rings, and
X5P adduct, demonstrates a largely conserved pattern
of interactions between the modeled TKTL1 and TKTL2
and the co-factor adduct, when compared to the TKT crys-
tal structure (Fig. 6). This strongly suggests that TKTL1
and TKTL2 can stably associate with the TDP-X5P inter-
mediate. Of note, the catalytic residue E366, shown to be
essential for catalysis [25], is conserved in TKTL1 and
TKTL2, while H110 is conserved in TKTL2. Thus, apart
from a close structural equivalence, residues crucial for
catalytic function is also conserved in TKTL2. It therefore
seems very likely that TKTL2 can act as a transketolase.
However, will the absence of H110 in TKTL1 abolish
its transketolase activity? It appears that alternative
active residue patterns are possible in transketolases,
suggesting some structural and functional degeneracy.
For example, yeast transketolase utilizes H481 and H103
to bind to a water molecule, through which the thiazole
C2 proton is indirectly abstracted. Mutation of the H481
residue abolished enzyme activity [26]. Intriguingly, in
human TKT a glutamine residue (Q428) is present at the
position equivalent to yeast H481 (Fig. 1). Mutation of
Q428 resulted in a 3- to 4-fold reduction, but not a loss
of TKT activity [27]. However, the mutation of H110 in
human TKT (equivalent to yeast H103) resulted in a
50-fold reduction in activity, effectively abolishing enzyme
function [27]. Thus, for human TKT the proposal is made
that H110 and H77 pair functioned like the yeast H481
and H103 pair, where H110 and H481, respectively, acted
as ultimate acceptors of the thiazole C2 proton.
Because of its value in biocatalysis, there has been a
number of mutational and directed evolution studies of
transketolases [28]. Although several interesting muta-
tions were identified that resulted in relaxed substrate
specificity and enhanced activity [28], there was no clear
identification of a residue that could act as alternative
proton acceptor to H110 or H481. However, the possible
mechanistic impact of the absence of H110 and H77 in
TKTL1 on possible catalytic activity is far from resolved
in the literature. For example, Titmann and colleagues
reported that deletion of a 38 residue region in TKT mim-
icked the observed deletion found in TKTL1 (containing
H110 and H77) and abolished transketolase activity [29].
However, the recombinant deletion protein was not
properly folded and it did not dimerize efficiently. Since
dimerization is a requirement for the formation of a
functional active site, where both sub-units contribute
essential residues, it is not clear that this study provides
any insights into TKTL1 functionality. A related study
also reported the absence of transketolase activity for a
recombinant human transketolase (38 residues deleted).
However, other than noting that the protein was recov-
ered from inclusion bodies in the bacterial hosts, this
study did not assess folding and dimerization of the
overexpressed protein [14].
Transketolase catalyzes the transfer of a 2-carbon
ketose from a donor such as X5P to an acceptor such
as ribose-5-P to produce sedoheptulose-7-P and
glyceraldehyde-3-P in a classic ping-pong-bi-bi
two-substrate reaction. An alternative reaction is the
one-substrate reaction, where the ketose derived from
the X5P donor dissociates from the active site to pro-
duce glycolaldehyde, which then acts as acceptor for
another ketose to produce erythrose [30]. Some re-
ported that the two-substrate reaction was decreased
by two-fold in a H103A mutant yeast protein [31]. Of
note, the one-substrate X5P reaction was enhanced by
~ two-fold to a level similar to the two-substrate reac-
tion in the H103A mutant protein [31]. However, in
yeast the H481 proton sink is still present in the H103
mutant. This is unlike the human enzyme where the
structural homolog of H103 is H110, the functional
equivalent of yeast H481.
Studies that expressed recombinant TKTL1 (versus TKT
deletion mutants to mimic TKTL1) or that assayed en-
dogenous TKTL1, reported transketolase activity [6, 32].
Here the recombinant TKTL1 protein exhibited both
classic two-substrate activity, utilizing X5P and ribose-
5-phosphate, as well as one-substrate specificity, utiliz-
ing only X5P [6]. Furthermore, others demonstrated
that siRNA knockdown of TKTL1 in cultured human
leukemia cells caused a significant decrease in TKT ac-
tivity that was measured by glyceraldehyde-3-P produc-
tion in the two-substrate X5P and ribose-5-P reaction
[32]. No direct data on possible non-specific knock-
down of TKT was provided, but the authors concluded
that TKTL1 possesses TKT activity [32].
In light of these two studies demonstrating TKT activity
for recombinant [6] and endogenous [32] TKTL1, and that
the latter apparently lacks the equivalent of H110, the
question naturally arises which residue acts as terminal ac-
ceptor to the thiazole C2 proton? An evaluation of the dis-
tribution of histidine residues in the region of the thiazole
C2 and aminopyrimidine amino groups, shows that H231
in TKTL1 is structurally equivalent to H258 in TKT
(Fig. 4a). The τ-nitrogen of H231 (like H258) is also
within hydrogen-bond distance of the thiazole sulphur.
It is therefore likely that H231 may act as acceptor to
the C2 proton to activate the thiazole ring. For TKT
the H110 residue is the preferred acceptor and may in
addition stabilize the co-factor-substrate intermediate
(Fig. 5a). It is thus possible that the absence of H110 in
TKTL1 weakens the interaction with the ketose reac-
tion intermediate, allowing for the dissociation of gly-
colaldehyde and enhancing the one-substrate reaction.
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Conclusions
Together these results support our hypothesis that TKTL1
and TKTL2 are functional transketolases and thus opens
up the possibility that altered activity/function may be
implicated in diseases such as diabetes and cancer. Add-
itional physiological and biochemical studies should
therefore be pursued to assess how modulation of such
enzymes may be exploited as putative therapeutic inter-
ventions for diabetes and cancer.
Additional files
Additional file 1: TKTL1_model: TKTL1 in covalent complex. X-ray
diffraction data. (PDF 2100 kb)
Additional file 2: TKTL2_model: TKTL2 in covalent complex. X-ray
diffraction data. (PDF 2185 kb)
Abbreviations
NADPH: Nicotinamide adenine dinucleotide phosphate; NOGP: Non-oxidative
glucose pathway; PPP: Pentose phosphate pathway; TDP: Thiamine
diphosphate; TKT: Transketolase; TKTL1: Transketolase-like 1;
TKTL2: Transketolase-like 2; X5P: D-xylulose-5-phosphate
Acknowledgements
None.
Funding
Stellenbosch University.
Availability of data and materials
The homology models for TKTL1 and TKTL2 in PDB format are available as
supplementary material.
Authors’ contributions
HGP, GD and MFE designed the research, HGP performed the research and
analyzed the data, and HGP, GD and MFE wrote the paper. All authors read
and approved the final version of this manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
“The authors declare that they have no competing interests.”
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Cardio-Metabolic Research Group (CMRG), Department of Physiological
Sciences, Stellenbosch University, Room 2005, Mike De Vries Building,
Merriman Avenue, Stellenbosch 7600, South Africa. 2Centre for Bioinformatics
and Computational Biology, Stellenbosch University, Stellenbosch 7600,
South Africa.
Received: 17 January 2018 Accepted: 13 December 2018
References
1. Coy JF, Dubel S, Kioschis P, Thomas K, Micklem G, Delius H, Poustka A.
Molecular cloning of tissue-specific transcripts of a transketolase-related
gene: implications for the evolution of new vertebrate genes. Genomics.
1996;32(3):309–16.
2. Lindqvist Y, Schneider G, Ermler U, Sundstrom M. Three-dimensional
structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.
5 a resolution. EMBO J. 1992;11(7):2373–9.
3. Zhao J, Zhong CJ. A review on research progress of transketolase. Neurosci
Bull. 2009;25(2):94–9.
4. Butterworth RF, Gaudreau C, Vincelette J, Bourgault AM, Lamothe F, Nutini
AM. Thiamine deficiency and Wernicke's encephalopathy in AIDS. Metab
Brain Dis. 1991;6(4):207–12.
5. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, Perrino P.
Reduced activities of thiamine-dependent enzymes in the brains and
peripheral tissues of patients with Alzheimer's disease. Arch Neurol. 1988;
45(8):836–40.
6. Coy JF, Dressler D, Wilde J, Schubert P. Mutations in the transketolase-like
gene TKTL1: clinical implications for neurodegenerative diseases, diabetes
and cancer. Clin Lab. 2005;51(5–6):257–73.
7. Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany
R, Lee WN, Boros LG, Cascante M. Oxythiamine and
dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor
cells through inhibition of the pentose cycle. FEBS Lett. 1999;456(1):113–8.
8. Jayachandran A, Lo PH, Chueh AC, Prithviraj P, Molania R, Davalos-Salas M,
Anaka M, Walkiewicz M, Cebon J, Behren A. Transketolase-like 1 ectopic
expression is associated with DNA hypomethylation and induces the
Warburg effect in melanoma cells. BMC Cancer. 2016;16:134.
9. Foldi M, Stickeler E, Bau L, Kretz O, Watermann D, Gitsch G, Kayser G,
Zur Hausen A, Coy JF. Transketolase protein TKTL1 overexpression: a
potential biomarker and therapeutic target in breast cancer. Oncol Rep.
2007;17(4):841–5.
10. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N,
Popa J, Ternullo MP, Steidler A, Weiss C, et al. Expression of transketolase
TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect
reinterpreted. Br J Cancer. 2006;94(4):578–85.
11. Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, Huang JS.
The TKTL1 gene influences total transketolase activity and cell proliferation
in human colon cancer LoVo cells. Anti-Cancer Drugs. 2007;18(4):427–33.
12. Zhang M, Chai YD, Brumbaugh J, Liu X, Rabii R, Feng S, Misuno K,
Messadi D, Hu S. Oral cancer cells may rewire alternative metabolic
pathways to survive from siRNA silencing of metabolic enzymes. BMC
Cancer. 2014;14:223.
13. Mitschke L, Parthier C, Schroder-Tittmann K, Coy J, Ludtke S, Tittmann K. The
crystal structure of human transketolase and new insights into its mode of
action. J Biol Chem. 2010;285(41):31559–70.
14. Meshalkina LE, Drutsa VL, Koroleva ON, Solovjeva ON, Kochetov GA. Is
transketolase-like protein, TKTL1, transketolase? Biochim Biophys Acta. 2013;
1832(3):387–90.
15. Maslova AO, Meshalkina LE, Kochetov GA. Computer modeling of
transketolase-like protein, TKTL1, a marker of certain tumor tissues.
Biochemistry (Mosc). 2012;77(3):296–9.
16. Nilsson U, Meshalkina L, Lindqvist Y, Schneider G. Examination of substrate
binding in thiamin diphosphate-dependent transketolase by protein
crystallography and site-directed mutagenesis. J Biol Chem. 1997;272(3):
1864–9.
17. Ludtke S, Neumann P, Erixon KM, Leeper F, Kluger R, Ficner R, Tittmann K.
Sub-angstrom-resolution crystallography reveals physical distortions that
enhance reactivity of a covalent enzymatic intermediate. Nat Chem. 2013;
5(9):762–7.
18. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using
the Robetta server. Nucleic Acids Res. 2004;32(Web Server):W526–31.
19. Benkert P, Kunzli M, Schwede T. QMEAN server for protein model quality
estimation. Nucleic Acids Res. 2009;37(Web Server issue):W510–4.
20. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ,
Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure
validation for macromolecular crystallography. Acta Crystallogr D Biol
Crystallogr. 2010;66(Pt 1):12–21.
21. Luthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-
dimensional profiles. Nature. 1992;356(6364):83–5.
22. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE. UCSF chimera--a visualization system for exploratory research and
analysis. J Comput Chem. 2004;25(13):1605–12.
23. Meng EC, Pettersen EF, Couch GS, Huang CC, Ferrin TE. Tools for
integrated sequence-structure analysis with UCSF chimera. BMC
Bioinformatics. 2006;7:339.
Deshpande et al. BMC Structural Biology            (2019) 19:2 Page 9 of 10
24. Mills JE, Dean PM. Three-dimensional hydrogen-bond geometry and
probability information from a crystal survey. J Comput Aided Mol Des.
1996;10(6):607–22.
25. Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM,
Taly JF, Notredame C. T-coffee: a web server for the multiple sequence
alignment of protein and RNA sequences using structural information and
homology extension. Nucleic Acids Res. 2011;39(Web Server issue):W13–7.
26. Robert X, Gouet P. Deciphering key features in protein structures with the
new ENDscript server. Nucleic Acids Res. 2014;42(Web Server issue):W320–4.
27. Singleton CK, Wang JJ, Shan L, Martin PR. Conserved residues are
functionally distinct within transketolases of different species. Biochemistry.
1996;35(49):15865–9.
28. Ranoux A, Hanefeld U. Improving Transketolase. Top Catalyst. 2013;56:750–64.
29. Lyskov S, Gray JJ. The RosettaDock server for local protein-protein docking.
Nucleic Acids Res. 2008;36(Web Server):W233–8.
30. Bykova IA, Solovjeva ON, Meshalkina LE, Kovina MV, Kochetov GA. One-
substrate transketolase-catalyzed reaction. Biochem Biophys Res Commun.
2001;280(3):845–7.
31. Selivanov VA, Kovina MV, Kochevova NV, Meshalkina LE, Kochetov GA.
Kinetic study of the H103A mutant yeast transketolase. FEBS Lett. 2004;
567(2–3):270–4.
32. Diaz-Moralli S, Aguilar E, Marin S, Coy JF, Dewerchin M, Antoniewicz MR,
Meca-Cortes O, Notebaert L, Ghesquiere B, Eelen G, et al. A key role for
transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016.
33. Xu ZP, Wawrousek EF, Piatigorsky J. Transketolase haploinsufficiency reduces
adipose tissue and female fertility in mice. Mol Cell Biol. 2002;22(17):6142–7.
34. Boyle L, Wamelink MM, Salomons GS, Roos B, Pop A, Dauber A, Hwa V,
Andrew M, Douglas J, Feingold M, et al. Mutations in TKT are the cause of a
syndrome including short stature, developmental delay, and congenital
heart defects. Am J Hum Genet. 2016;98(6):1235–42.
Deshpande et al. BMC Structural Biology            (2019) 19:2 Page 10 of 10
